Salem, Haitham published the artcileRevisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges, Category: triazoles, the publication is Current Neuropharmacology (2017), 15(5), 789-798, database is CAplus and MEDLINE.
A review. Background: Akathisia continues to be a significant challenge in current neurol. and psychiatric practice. Prompt and accurate detection is often difficult and there is a lack of consensus concerning the neurobiol. basis of akathisia. No definitive treatment has been established for akathisia despite numerous preclin. and clin. studies. Method: We reviewed antipsychotic-induced akathisia including its clin. presentation, proposed underlying pathophysiol., current and under investigation therapeutic strategies. Conclusion: Despite the initial promise that second generation antipsychotics would be devoid of akathisia effects, this has not been confirmed. Currently, there are limited therapeutic options for the clin. practice and the evidence supporting the most widely used treatments (beta blockers, anticholinergic drugs) is still absent or inconsistent.
Current Neuropharmacology published new progress about 377727-87-2. 377727-87-2 belongs to triazoles, auxiliary class GPCR/G Protein,Adenosine Receptor, name is 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, and the molecular formula is C25H29N9O3, Category: triazoles.
Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics